Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
RESEARCH TOOLSreports
ARVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.61 - $51.99
Previous CloseN/A
Volume216.17K
Average Volume (3M)957.07K
Market Cap
$1.28B
Enterprise Value$655.72M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.88
Next Earnings
May 06, 2025EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.17
Shares Outstanding68,771,866
10 Day Avg. Volume1,249,756
30 Day Avg. Volume957,066
Standard Deviation0.38
R-Squared0.07
Alpha-0.00197
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.87
Price to Cash Flow (P/CF)-3.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.49
Enterprise Value/Ebitda-2.67
Forecast
1Y Price Target
$63.64Price Target Upside246.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company remains on track to initiate a Phase 3 trial evaluating vepdeg + atirmo in 1L patients and a Phase 2 trial evaluating vepdeg + CDK4/6i in 2L patients.
Financial StabilityThe company reported $1,039mn in cash and cash equivalents, which the company indicated will provide cash runway into 2027.
Product PotentialConfidence in vepdegestrant's potential in the ESR1-mutant population is high, and its value in these patients alone justifies a premium to today's current price.
Bears Say
Investor SentimentInvestor sentiment around ARVN's PROTAC platform and SERDs have remained negative and implies anything less than a benefit in the ESR1 wild-type patients of the VERITAC-2 study is failure.
Leadership ChangesThe Chief Commercial Officer (CCO) stepped down last month due to personal reasons and has been replaced by an interim CCO.
Product DifferentiationDifferentiation from SERDs, particularly in the front-line and fulvestrant-naive settings, is a major question.
---
Ownership Overview
2.66% Insiders
25.37% Mutual Funds
0.41% Other Institutional Investors
56.21% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $16.61 and its highest was $51.99 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $1.28B.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is May 06, 2025 which is in 74 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on Feb 11, 2025. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.955 by $0.325.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -1.02.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 68,771,866 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.955. Following the earnings report the stock price went down -6.8%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
---
Arvinas Holding Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.64 (246.43% Upside)
$63.64 (246.43% Upside)
Insider Transactions
Sold Shares
Worth $10.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.4%
Last 30 Days ▲ 21.5%
Last 30 Days ▲ 21.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.55%
12-Months-Change
Fundamentals
Return on Equity
-35.41%
Trailing 12-Months
Asset Growth
-16.34%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
---
ARVN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook for Arvinas, with strong financial results, significant pipeline advancements, and strategic initiatives in place for future growth. Although there are some challenges, such as increased expenses and a leadership change, the overall progress and strategic positioning outweigh these concerns.Read More>---
ARVN Stock 12 Month Forecast
Average Price Target
$63.64
▲(246.43% Upside)
Technical Analysis
Blueprint Medicines
―
CytomX Therapeutics
―
Nurix Therapeutics
―
Kymera Therapeutics
―
Biohaven Ltd.
―
Best Analysts Covering ARVN
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+4.06%
reiterated a buy rating 11 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +4.06% per trade.
---